CORPORATE PRESENTATION
We invite you to download our corporate presentation to help understand our unique purpose, our current commercial footprint, and our innovative pipeline.
Quarterly Results
Press Releases
The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis (IPF) preserved lung function as measured by absolute forced vital capacity (FVC) and...
17 May 2026
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
The long-term, pivotal, phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag achieving a statistically significant 55% reduction in risk of clinical worsening in predominantly pre-treated patients with...
First-ever human clinical trial of a xenoheart intended to support potential registration through the submission of a Biologics License Application to the U.S. FDASILVER SPRING, Md. & RESEARCH TRIANGLE PARK...
12 May 2026
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond,Chief Financial Officer and Treasurer, will provide a company...
Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in idiopathic pulmonary fibrosis (IPF) include efficacy and safety results from TETON-1 and integrated results from TETON-1...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31,...
Events and presentations
19 May 2026
RBC Capital Markets Global Healthcare Conference
09:30 AM ET
06 May 2026
United Therapeutics First Quarter 2026 Financial Results
09:00 AM ET
09 Mar 2026
Leerink Global Healthcare Conference
01:00 PM ET
02 Mar 2026
TD Cowen Health Care Conference
02:30 PM ET
02 Mar 2026
Phase 3 ADVANCE OUTCOMES Clinical Trial Results
08:30 AM ET
25 Feb 2026
United Therapeutics Fourth Quarter and Full Year 2025 Financial Results
09:00 AM ET